» Articles » PMID: 14731049

The Generation Gap: Differences Between Children and Adults Pertinent to Economic Evaluations of Health Interventions

Overview
Specialty Pharmacology
Date 2004 Jan 21
PMID 14731049
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Differences between children and adults have both technical and ethical implications for the design, interpretation and employment of economic analyses of health-related programmes. Even though policy makers increasingly turn to economic analyses to inform decisions about resource allocation, pertinent child-adult differences have received fragmented discussion in leading methodological references. Key areas warranting attention include: the ways in which a child's distinctive biology modifies the cost and effectiveness of healthcare interventions; challenges in assessing utilities for infants and young children given their limited but developing cognitive capacity; how a child's age, dependency and disability affect the selection of the appropriate time horizon and scope of the analysis; whether a child's non-wage earning productivity should be incorporated into analyses, and if so, what metric to use; what principles of equity policy makers should employ in using economic evaluations to choose between child- and adult-focused interventions; and whether special protective measures should be introduced to secure the rights and interests of children who cannot advocate for themselves.

Citing Articles

Economic evaluations of medical devices in paediatrics: a systematic review and a quality appraisal of the literature.

Mascarenhas E, Miguel L, Oliveira M, Fernandes R Cost Eff Resour Alloc. 2024; 22(1):33.

PMID: 38678250 PMC: 11056067. DOI: 10.1186/s12962-024-00537-0.


A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects.

Lamsal R, Yeh E, Pullenayegum E, Ungar W Pharmacoeconomics. 2023; 42(2):199-217.

PMID: 37945777 PMC: 10810985. DOI: 10.1007/s40273-023-01331-1.


Access to novel drugs and therapeutics for children and youth: Eliciting citizens' values to inform public funding decisions.

Gauvreau C, Wight L, Subasri M, Palmer A, Hayeems R, Croker A Health Expect. 2023; 26(2):715-727.

PMID: 36639959 PMC: 10010086. DOI: 10.1111/hex.13697.


International guidelines for self-report and proxy completion of paediatric health-related quality of life measures: a protocol for a systematic review.

Mpundu-Kaambwa C, Chen G, Dalziel K, Devlin N, Ratcliffe J BMJ Open. 2021; 11(12):e052049.

PMID: 34880018 PMC: 8655531. DOI: 10.1136/bmjopen-2021-052049.


Does moral reasoning influence public values for health care priority setting?: A population-based randomized stated preference survey.

Denburg A, Ungar W, Chen S, Hurley J, Abelson J Health Policy. 2020; 124(6):647-658.

PMID: 32405121 PMC: 7219374. DOI: 10.1016/j.healthpol.2020.04.007.


References
1.
Jenney M, Campbell S . Measuring quality of life. Arch Dis Child. 1997; 77(4):347-50. PMC: 1717359. DOI: 10.1136/adc.77.4.347. View

2.
Pedersen S, Warner J, Wahn U, Staab D, Le Bourgeois M, Arora S . Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics. 2002; 109(6):e92. DOI: 10.1542/peds.109.6.e92. View

3.
Cretin S . Cost/benefit analysis of treatment and prevention of myocardial infarction. Health Serv Res. 1977; 12(2):174-89. PMC: 1071979. View

4.
Detsky A, Naglie I . A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990; 113(2):147-54. DOI: 10.7326/0003-4819-113-2-147. View

5.
Keren R, Helfand M, Homer C, McPhillips H, Lieu T . Projected cost-effectiveness of statewide universal newborn hearing screening. Pediatrics. 2002; 110(5):855-64. DOI: 10.1542/peds.110.5.855. View